On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
ORGANIZATION
JPMA Policy Proposal Calls for Govt’s Flexibility towards Coronavirus Vaccinations, Steps to Expedite Visas for Foreign Technicians
The Japan Pharmaceutical Manufacturers Association (JPMA) has formulated a policy proposal to tackle practical challenges associated with COVID-19 vaccinations, calling for flexible measures to address issues anticipated at a time when vaccine development is moving with unprecedented speed. The proposal,…
To read the full story
Related Article
ORGANIZATION
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…